Episode 12: Matt Angle Talks Paradromics and BCI Market Dynamics

7 Sept

For people who have lost the ability to speak, brain-computer interfaces (BCIs) could open a new path back to communication. In this episode, Adam Fraser speaks with Matt Angle, founder and CEO of Paradromics, about the company’s 11-year journey to build a BCI that can restore communication for people who have lost it. Matt explains why moving more neural data is central to BCI performance and how Paradromics is approaching safety, durability and clinical translation. He breaks down why speech restoration is the company’s first clinical focus, then unpacks what could come next, including movement applications, mood biomarkers and AI-enabled communication. The conversation also explores the company’s move from Silicon Valley to Austin, Texas, as well as the regulatory, reimbursement, funding and commercial realities of building in deep tech, and what it takes to turn frontier neuroscience into a durable company. Listen in for a closer look at Paradromics’ journey and the technology, capital and strategic thinking shaping the future of BCI.

Key Points From This Episode:

[01:31] Discover how Matt’s neuroscience background led him to found Paradromics.
[03:18] Learn how BCI has shifted from pure science to an engineering challenge.
[04:53] Hear why Matt has stayed in the CEO role 11 years into the journey.
[07:34] Understand Paradromics’ focus on safety, durability and neural data.
[08:29] Why moving more neural data is central to building better BCI systems.
[14:00] Learn why speech restoration is Paradromics’ first clinical focus.
[15:20] Explore the broader medical applications Paradromics may pursue next.
[20:11] Find out why Paradromics moved from Silicon Valley to Austin, Texas.
[22:25] Matt’s perspective on FDA engagement, regulation and reimbursement pathways.
[27:26] Explore how Paradromics thinks about funding, competition and investor alignment.
[33:28] Hear Matt’s view on IPO potential and the wider BCI ecosystem.
[35:18] Why “invasive” is not always the best way to assess BCI risk.
[39:29] Matt’s advice for founders building deep tech companies.